SAN FRANCISCO, March 29, 2016 /PRNewswire/ -- Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Rinko Ghosh, President and Chief Business Officer, will present at the BIO Europe Spring Conference in Stockholm. The presentation will address the potential for new therapies in the area of oncology that target the ECM.
Conference details are as follows:
Date: Tuesday, Apr. 5, 2016
Time: 11:15 a.m. CEST
Location: Room E5 Level 0, Kistamässan Convention Center, Stockholm, Sweden
About Symic
Symic is a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, which are important structural and functional macromolecules native to the ECM, play a critical role in healing following injury and in chronic diseases. Symic’s proprietary compounds function like proteoglycans, and have been designed to promote healing and repair in a variety of disease states. Symic has two clinical candidates, one in vascular injury and the other in osteoarthritis. In addition, Symic has several preclinical programs in oncology, fibrosis and CNS disorders.
Symic is based in San Francisco. For additional information, please visit the company’s website at http://www.symic.bio or follow us on Twitter at www.twitter.com/symicbio and LinkedIn at www.linkedin.com/company/symic-bio/.
Media Contacts
David Schull or Lena Evans
Russo Partners, LLC
(212) 845-4271
(212) 845-4262
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symic-to-present-at-the-bio-europe-spring-conference-300241727.html
SOURCE Symic
